Brief: Neurocrine Biosciences Initiates Phase 2 Study Of Crinecerfont In Pediatric Patients Under 4 Years Old With Classic Congenital Adrenal Hyperplasia
01/07/2026 21:11
BRIEF-Neurocrine Biosciences Initiates Phase 2 Study Of Crinecerfont In Pediatric Patients Under 4 Years Old With Classic Congenital Adrenal Hyperplasia July 1 (Reuters) - Neurocrine Biosciences, Inc NBIX.O:
NEUROCRINE BIOSCIENCES INITIATES PHASE 2 STUDY OF CRINECERFONT IN PEDIATRIC PATIENTS UNDER 4 YEARS OLD WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA
Source text: ID:nPn27r6B3a
Further company coverage: NBIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurocrine Biosciences
See all newsBrief: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall